Annexon’s (ANNX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Annexon (NASDAQ:ANNX) in a report released on Tuesday morning,Benzinga reports. They currently have a $30.00 price objective on the stock.

Several other equities analysts have also recently issued reports on ANNX. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and set a $16.00 price target on shares of Annexon in a research report on Friday, November 15th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $15.80.

Annexon Price Performance

NASDAQ:ANNX opened at $5.22 on Tuesday. The company’s fifty day moving average price is $6.21 and its 200-day moving average price is $5.97. Annexon has a 1-year low of $2.77 and a 1-year high of $8.40. The firm has a market capitalization of $556.42 million, a P/E ratio of -4.97 and a beta of 1.10.

Insider Buying and Selling

In related news, EVP Ted Yednock sold 5,408 shares of the company’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $7.41, for a total transaction of $40,073.28. Following the completion of the transaction, the executive vice president now owns 71,365 shares in the company, valued at $528,814.65. This represents a 7.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 12.67% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Annexon

Several large investors have recently bought and sold shares of the company. Franklin Resources Inc. acquired a new stake in shares of Annexon in the third quarter worth approximately $292,000. Barclays PLC boosted its stake in Annexon by 212.0% during the 3rd quarter. Barclays PLC now owns 177,765 shares of the company’s stock worth $1,052,000 after purchasing an additional 120,789 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Annexon by 18.3% during the third quarter. Geode Capital Management LLC now owns 2,143,635 shares of the company’s stock worth $12,693,000 after buying an additional 331,269 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Annexon by 36.2% in the third quarter. Wellington Management Group LLP now owns 263,360 shares of the company’s stock valued at $1,559,000 after buying an additional 69,941 shares during the last quarter. Finally, State Street Corp lifted its stake in shares of Annexon by 116.6% in the third quarter. State Street Corp now owns 3,841,879 shares of the company’s stock worth $22,744,000 after buying an additional 2,068,294 shares in the last quarter.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.